Group items tagged

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The American Psychological Association is accepting applications for its Elizabeth Munsterberg Koppitz Fellowship program, which is designed to nurture excellent young scholars for careers in areas of psychology, such as child-clinical, pediatric, school, educational and developmental psychopathology. Through the program, one-year grants of up to $25,000 will be awarded to support graduate research projects and scholarships in child psychology. To be eligible, applicants must have completed doctoral candidacy at the time of application (documentation required) and demonstrated research competence and area commitment. In addition, IRB approval must be received from their host institution before funding can be awarded if human participants are involved.

The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To that end, the McKnight Endowment Fund for Neuroscience invites Letters of Intent for its 2018 McKnight Technological Innovations in Neuroscience awards. The program encourages and supports scientists working on the development of novel and creative approaches to the understanding of brain function. McKnight is interested in how a new technology may be used to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. Because the program seeks to advance and enlarge the range of technologies available to the neurosciences, research based primarily on existing techniques will not be considered. A goal of the Technological Innovations awards is to foster collaboration between the neurosciences and other disciplines; therefore, collaborative and cross-disciplinary applications are explicitly invited.

The annual program supports graduate-level scholarly projects that employ a psychological perspective to help deepen understanding of and reduce stigma associated with mental illness. The $5,000 scholarship helps address research which shows that stigma is a significant barrier to treatment and recovery for many of the 50 million Americans living with mental illness. To be eligible, applicants must be a full-time graduate students in good standing at an accredited university and have demonstrated commitment to stigma issues.

The Substance Abuse and Mental Health Services Administration (SAMHSA) is accepting applications for fiscal year (FY) 2019 Mental and Substance Use Disorder (SUD) Practitioner Data grant. The purpose of this program is to provide comprehensive data and analysis on individuals who comprise the prevention and treatment fields to address mental and substance use disorders. The goal of the program is to provide valid data on the existing practitioners and usable information to SAMHSA on which to make policy and planning decisions.

This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use.

The goal of this DCL is to encourage partnerships with and among MSIs in order to promote fundamental research, perspectives, and ideas in the SBE sciences. NSF's hope is that this new initiative will build capacity at MSIs for SBE-related research and provide researchers with new ways to diversify and energize their research teams. NSF anticipates funding up to 10 conferences pursuant to this DCL, subject to the availability of funds and the quality of proposals received. Proposals may address any of the scientific areas supported by SBE. Proposals can come directly from HBCUs, HSIs, TCUs and other MSIs, or from any other NSF-eligible research entity. Proposers are strongly encouraged to plan to host and design conferences at the MSI campus identified in the proposal.